TQ Quiz | Pharmaceutical Update 2025 (Pittsburgh 2025)

"*" indicates required fields

This field is hidden when viewing the form

@{:35}

This field is hidden when viewing the form

Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event 90 days past date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date Difference (Hidden)

1. In the pharmaceutical resource matrix who is the best person for to discuss an “off-label” question or usage of the pharmaceutical:*

A - Local sales representative

B - Regional sales representative

C - National sales representative

D - Medical science liaison

2. When it comes to tear volume. What is the capacity for topical medication?*

A - 10 microliters

B - 30 microliters

C - 50 microliters

D - 70 microliters

3. If you are treating glaucoma with topical medications. Which anterior segment condition is most likely to result?*

A - Keratoconus

B - Fuchs Dystrophy

C - Ocular surface disease

D - Pterygium

4. The innate, adaptive, and complement systems are all parts of:*

A - Digestive system

B - Immune system

C - Circulatory system

D - Skeletal system

5. One of the best techniques or instruments to follow or management geographic atrophy is:*

A - Ocular response analyzer (ORA)

B - Cornea topography

C - Fundus autofluorescence (FAF)

D - OCT evaluation of the ganglion cell complex (GCC) and retina Nerve Fiber Layer (rNFL)

6. In February 2023 the FDA approved the first Treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) this pharmaceutical is:*

A - Syfovre (pegcetacoplan)

B - Eylea (aflibercept)

C - Vabysmo (faricimab-svoa)

D - Xdemvy (lotilaner ophthalmic solution) 0.25%

7. Syfovre (pegcetacoplan) mechanism of action is regulating excessive activation of the complement cascade. Which part of the complement system is it inhibiting?*

A - C1

B - C2

C - C3

D - C10

8. Izervay (avacincaptad pegol intravitreal solution) is FDA indicated for which ocular condition?*

A - Keratoconus

B - Vitreal floaters

C - Glaucoma

D - Geographic atrophy (AMD)

9. Izervay (avacincaptad pegol intravitreal solution) mechanism of action is regulating excessive activation of the complement cascade. Which part of the complement system is it inhibiting?*

A - C1

B - C2

C - C5

D - C10

10. Eylea (aflibercept) as of January 2024 is indicated to treat ___retinal conditions caused by ocular angiogenesis:*

A - 1

B - 5

C - 10

D - 20

11. Which pharmaceutical has a mechanism of action that inhibits vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of wet AMD or diabetic macular edema (DME)?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Vabysmo (faricimab-svoa)

12. Which biologic drug is an injection and is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), it offers a 3-month dosing schedule in the first year of treat, but when used resulted in an adverse intraocular inflammation events?*

A - Bevacizumab (Avastin)

B - Ranibizumab (Lucentis)

C - Aflibercept (Eylea)

D - Brolucizumab-dbll (Beovu)

13. Which pharmaceutical was approved in July 2023 by the FDA to treat Demodex blepharitis?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

14. Which pharmaceutical works as an antiparasitic agent to target parasite-specific GABA-Chloride (Cl) channels*

A - Miebo (perfluorohexyloctane ophthalmic solution) 100%

B - Xdemvy (lotilaner ophthalmic solution) 0.25%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

15. Which pharmaceutical was approved in May 2023 by the FDA to treat the signs and symptoms of dry eye?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

16. Which pharmaceutical was approved in October 2023 by the FDA to treat the signs and symptoms of presbyopia?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

17. Which preservative free pharmaceutical was approved in December 2022 by the FDA for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension?*

A - Xdemvy (lotilaner ophthalmic solution) 0.25%

B - Miebo (perfluorohexyloctane ophthalmic solution) 100%

C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%

D - Iyuzeh (latanoprost ophthalmic solution) 0.005%

18. Which pharmaceutical was approved in September 2023 by the FDA for the treatment of pharmacologically induced mydriasis (dilation reversal) produced by adrenergics?*

A - Tropicamide 0.5%

B - Tropicamide 1.0%

C - Ryzumvi (phentolamine ophthalmic solution) 0.75%

D - Mycombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1% / 2.5%

19. Which of these glaucoma medications is considered a Rho kinase or ROCK NET inhibitor?*

A - Timolol maleate

B - Latanoprost

C - Bimatoprost

D - Netarsudil

20. Which biologic agent used for FR-alpha positive platinum resistant ovarian cancer (PROC) needs cleared and monitored by an eye care physician due to superficial keratopathy, corneal deposits, and keratitis?*

A - Cenegermin-bkbj (Oxervate)

B - Teprotumumab-trbw (Tepezza)

C - Mirvetuximab Soravtansine (Elahere)

D - Tocilizumab (Actemra)

Personal Information

Name*

First Last

Email*

Phone*

OE Tracker #

License #

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Payment Information

Promotional Code

Pittsburgh 2025 - Pharmaceutical Update 2025 | TQ*

After 90 days, pricing will increase to $30.

Price:

(Past 90 Days) Pittsburgh 2025 - Pharmaceutical Update 2025 | TQ

This course was presented over 90 days ago. Due to this late submission of TQ, your TQ credit price is $30.

Price:

Retake Discount

Price:

Promotional Discount

Price:

(Past 90 Days) Retake Discount

Price:

(Past 90 Days) Promotional Discount

Price:

Credit Card*

This field is hidden when viewing the form

Course Information (HIDDEN)

This field is hidden when viewing the form

Course Name (HIDDEN)

This field is hidden when viewing the form

Retake Code (HIDDEN)

This field is hidden when viewing the form

Quiz URL (HIDDEN)

Do not include ending backslash (aka no .com/)

This field is hidden when viewing the form

CE Hours

TQ Quiz | Pharmaceutical Update 2025 (Pittsburgh 2025)

@{:35}

Personal Information

Payment Information

Course Information (HIDDEN)

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

TQ Quiz | Pharmaceutical Update 2025 (Pittsburgh 2025)

@{:35}

Personal Information

Payment Information

Course Information (HIDDEN)

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

Subscribe For Event Updates